Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor
Introduction: It is worth noting the limitations in sensitivity of the existing biomarkers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in detection of colorectal cancer (CRC). In our study, we address the performance of the liquid biopsy biomarker ''methylated septin...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294223000709 |
| _version_ | 1797732870023806976 |
|---|---|
| author | Sabine Leerhoff Arnold Raem Ernst-Wolfgang Kolbe Laura Schulz Kirsten Borchers Thomas Köhler Günther Winde Carmen Kirchner |
| author_facet | Sabine Leerhoff Arnold Raem Ernst-Wolfgang Kolbe Laura Schulz Kirsten Borchers Thomas Köhler Günther Winde Carmen Kirchner |
| author_sort | Sabine Leerhoff |
| collection | DOAJ |
| description | Introduction: It is worth noting the limitations in sensitivity of the existing biomarkers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in detection of colorectal cancer (CRC). In our study, we address the performance of the liquid biopsy biomarker ''methylated septin 9'' (mSEPT9) in the detection and disease surveillance of CRC. Materials and Methods: The monocentric prospective survey encompassed 120 patients diagnosed with CRC who underwent planned curative resection between December 2018 and December 2020. Blood samples were collected from the participants preoperatively as well as at 7 days, 6 weeks, and 3 months postoperatively. The presence of mSEPT9, CEA, and CA 19-9 was detected using the pro Epi Colon® 2.0 CE test, Elecsys® CEA, and Elecsys® CA19-9 electrochemiluminescence immunoassay, respectively. Results: In the preoperative setting, mSEPT9 demonstrated superior capability in identifying patients with CRC compared to CEA and CA 19-9, with detection rates of 57%, 32%, and 18% respectively. Combining all three biomarkers increased the overall sensitivity to 66% preoperatively. In considering UICC stage and T-status, mSEPT9 exhibited higher sensitivity across all stages in comparison with conventional tumor markers, and 65% of patients with metastases were identified postoperatively through mSEPT9. Tumor recognition after surgery was achieved with the sensitivity of 72% and specificity of 91%. Conclusions: We recommend using mSEPT9 as a non-invasive diagnostic tool for the ongoing monitoring of patients with CRC. The sensitivity and specificity exhibited by mSEPT9 in recognition of tumor after surgery, highlights its particular potential for monitoring of CRC patients. |
| first_indexed | 2024-03-12T12:20:46Z |
| format | Article |
| id | doaj.art-8e745493be834b7daed3307816e338a0 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-03-12T12:20:46Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-8e745493be834b7daed3307816e338a02023-08-30T05:54:28ZengElsevierCancer Treatment and Research Communications2468-29422023-01-0136100748Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumorSabine Leerhoff0Arnold Raem1Ernst-Wolfgang Kolbe2Laura Schulz3Kirsten Borchers4Thomas Köhler5Günther Winde6Carmen Kirchner7Department of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, Germanyarrows biomedical Deutschland GmbH, Heisenbergstr. 1, 48149 Muenster, GermanyDepartment of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, GermanyDepartment of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, GermanyDepartment of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, GermanyDepartment of Anaesthesiology and Intensive Care Medicine, Klinikum Halberstadt, Gleimstr. 5, 38820 Halberstadt, GermanyDepartment of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, Germany; Corresponding author at: Department of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, Germany.Department of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Schwarzenmoorstr. 70, 32049 Herford, GermanyIntroduction: It is worth noting the limitations in sensitivity of the existing biomarkers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in detection of colorectal cancer (CRC). In our study, we address the performance of the liquid biopsy biomarker ''methylated septin 9'' (mSEPT9) in the detection and disease surveillance of CRC. Materials and Methods: The monocentric prospective survey encompassed 120 patients diagnosed with CRC who underwent planned curative resection between December 2018 and December 2020. Blood samples were collected from the participants preoperatively as well as at 7 days, 6 weeks, and 3 months postoperatively. The presence of mSEPT9, CEA, and CA 19-9 was detected using the pro Epi Colon® 2.0 CE test, Elecsys® CEA, and Elecsys® CA19-9 electrochemiluminescence immunoassay, respectively. Results: In the preoperative setting, mSEPT9 demonstrated superior capability in identifying patients with CRC compared to CEA and CA 19-9, with detection rates of 57%, 32%, and 18% respectively. Combining all three biomarkers increased the overall sensitivity to 66% preoperatively. In considering UICC stage and T-status, mSEPT9 exhibited higher sensitivity across all stages in comparison with conventional tumor markers, and 65% of patients with metastases were identified postoperatively through mSEPT9. Tumor recognition after surgery was achieved with the sensitivity of 72% and specificity of 91%. Conclusions: We recommend using mSEPT9 as a non-invasive diagnostic tool for the ongoing monitoring of patients with CRC. The sensitivity and specificity exhibited by mSEPT9 in recognition of tumor after surgery, highlights its particular potential for monitoring of CRC patients.http://www.sciencedirect.com/science/article/pii/S2468294223000709Colorectal cancerClinical prospective studyNon-invasive diagnosisDisease surveillanceLiquid biopsyMetastases |
| spellingShingle | Sabine Leerhoff Arnold Raem Ernst-Wolfgang Kolbe Laura Schulz Kirsten Borchers Thomas Köhler Günther Winde Carmen Kirchner Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor Cancer Treatment and Research Communications Colorectal cancer Clinical prospective study Non-invasive diagnosis Disease surveillance Liquid biopsy Metastases |
| title | Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor |
| title_full | Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor |
| title_fullStr | Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor |
| title_full_unstemmed | Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor |
| title_short | Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor |
| title_sort | methylated septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor |
| topic | Colorectal cancer Clinical prospective study Non-invasive diagnosis Disease surveillance Liquid biopsy Metastases |
| url | http://www.sciencedirect.com/science/article/pii/S2468294223000709 |
| work_keys_str_mv | AT sabineleerhoff methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT arnoldraem methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT ernstwolfgangkolbe methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT lauraschulz methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT kirstenborchers methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT thomaskohler methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT guntherwinde methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor AT carmenkirchner methylatedseptin9identifiedpatientswithcolorectalcarcinomaandshowedhighersensitivitythanconventionalbiomarkersindetectingtumor |